📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Assessment of Minimal Residual Disease in Standard-Risk AML. (2016)

First Author: Ivey A

Attributed to: Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours). funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1507471

PubMed Identifier: 26789727

Publication URI: http://europepmc.org/abstract/MED/26789727

Type: Journal Article/Review

Volume: 374

Parent Publication: The New England journal of medicine

Issue: 5

ISSN: 0028-4793